Published Paper Details:

ABSTRACT- In the present scenario of COVID-19, these promising drugs i.e. remdesivir, dexamethasone and favipiravir are a potential treatment option. The deadly SARS-COV-2 virus caused inflammation to the lungs and in severe cases, it leads to multiple organ failure. WHO approved emergency use of both the drugs for the patient who are hospitalized and require oxygen support. On one side, antiviral properties of remdesivir are used against SARS-COV-2, and on the other side, anti-inflammatory responses of dexamethasone are being utilized to treat the lung infection caused by the viral attack. Like any other drug, remdesivir, and dexamethasone, both have side effects. But, in the hour of need, these two have been reported to decrease the mortality rate. So short-term use of these drugs in critical patients is highly fruitful. Favipiravir is another repurposed antiviral agent that has recently come into the limelight for it's ability to clear the viremia very rapidly in the early part of the illness.